<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Endoscopic ultrasound-guided celiac plexus interventions for pain related to pancreatic disease
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Endoscopic ultrasound-guided celiac plexus interventions for pain related to pancreatic disease
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Endoscopic ultrasound-guided celiac plexus interventions for pain related to pancreatic disease
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Authors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Maurits J Wiersema, MD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Monica Saumoy, MD, MS
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Douglas G Adler, MD, FACG, AGAF, FASGE
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Kristen M Robson, MD, MBA, FACG
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            May 30, 2023.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Pancreatic cancer, cancer metastatic to the pancreas, and chronic pancreatitis are commonly associated with intense pain. Pharmacologic therapy such as nonsteroidal agents and opioids may be inadequate for controlling pain. In addition, opioids have been associated with side effects such as nausea and constipation and with concerns of opioid misuse and dependence. Non-pharmacologic therapies to control pain include nerve blocks that involve injection of a drug in proximity to the celiac plexus to provide analgesia. Interventions targeting the celiac plexus have been performed percutaneously with computed tomography-guidance or intraoperatively, while the endoscopic ultrasound (EUS)-guided approach has been increasingly utilized in clinical practice.
        </p>
        <p>
         This topic will review EUS-guided celiac plexus and other targeted interventions for managing pain related to pancreatic cancer and chronic pancreatitis.
        </p>
        <p>
         The diagnosis and management of pancreatic cancer are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/2501.html" rel="external">
          "Clinical manifestations, diagnosis, and staging of exocrine pancreatic cancer"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2477.html" rel="external">
          "Treatment for potentially resectable exocrine pancreatic cancer"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/85690.html" rel="external">
          "Treatment protocols for pancreatic cancer"
         </a>
         .)
        </p>
        <p>
         Assessment of cancer pain and the use of non-EUS interventions for managing pain are discussed separately:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/2795.html" rel="external">
          "Assessment of cancer pain"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/14248.html" rel="external">
          "Interventional therapies for chronic pain"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/2505.html" rel="external">
          "Supportive care for locally advanced or metastatic exocrine pancreatic cancer"
         </a>
         .)
        </p>
        <p>
        </p>
        <p>
         The clinical manifestations, diagnosis, and treatment of chronic pancreatitis are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/5649.html" rel="external">
          "Chronic pancreatitis: Clinical manifestations and diagnosis in adults"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/5647.html" rel="external">
          "Chronic pancreatitis: Management"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2">
         <span class="h1">
          ANATOMY OF THE CELIAC PLEXUS
         </span>
         <span class="headingEndMark">
          —
         </span>
         The celiac plexus is a dense network of nerves including sympathetic and parasympathetic efferent fibers and visceral sensory afferent fibers that innervate the upper abdominal organs [
         <a href="#rid1">
          1
         </a>
         ]. The celiac plexus mediates the sensation of pain from the pancreas and includes right and left ganglia that lie anterolateral to the aorta at the origin of the celiac trunk (ie, the first large vessel to branch from the aorta below the diaphragm). The celiac ganglia are typically located between T12 and L2 and, in most patients, two to five large ganglia are present [
         <a href="#rid2">
          2
         </a>
         ]. The celiac ganglia receive the splanchnic nerves from T5 to T12, which connect at the celiac plexus and pass through the crus of the diaphragm onto the spinal cord [
         <a href="#rid3">
          3
         </a>
         ]. The terms celiac plexus and splanchnic nerves are often used interchangeably, although they are anatomically distinct structures [
         <a href="#rid2">
          2
         </a>
         ]. Stimuli reach the thalamus and cortex of the brain, and this information is perceived as pain. Descending inhibitory mechanisms may also modulate the ascending pain information.
        </p>
        <p class="headingAnchor" id="H3471458868">
         <span class="h1">
          TERMINOLOGY
         </span>
         <span class="headingEndMark">
          —
         </span>
         Therapeutic nerve blocks involve injection of a drug in proximity to a nerve to provide pain relief. EUS-guided celiac plexus interventions involve drug injections at the level of the celiac artery.
        </p>
        <p>
         Common celiac plexus interventions are divided into the following:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Celiac plexus neurolytic block (ie, celiac plexus neurolysis) – EUS-guided celiac plexus neurolytic block is an intervention that permanently alters the affected nerve.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Celiac plexus nonneurolytic block (ie, celiac plexus block) – EUS-guided celiac plexus nonneurolytic block is an intervention that interrupts nerve transmission without permanently injuring the affected nerve.
        </p>
        <p>
        </p>
        <p>
         Other EUS-guided celiac plexus interventions include:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Celiac ganglia neurolytic block – EUS-guided celiac ganglia neurolytic block is an intervention involving drug injection directly into the celiac ganglia (also referred to as celiac ganglia neurolysis or simply celiac neurolysis).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Broad plexus neurolytic block – EUS-guided broad plexus neurolytic block (or broad plexus neurolysis) involves injecting a neurolytic agent at the level of the superior mesenteric artery, resulting in a broader distribution of neurolytic block. This is sometimes referred to as an extended celiac neurolysis.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1129059135">
         <span class="h1">
          CONTRAINDICATIONS
         </span>
         <span class="headingEndMark">
          —
         </span>
         There are few contraindications to EUS-guided celiac plexus interventions; however, most contraindications are related to routine upper endoscopy and include:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Patients who cannot tolerate moderate sedation, monitored anesthesia care, or general anesthesia. (See
         <a class="medical medical_review" href="/z/d/html/105511.html" rel="external">
          "Anesthesia for gastrointestinal endoscopy in adults"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Patients who are hemodynamically unstable.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Patients with abnormal coagulation studies (platelet count &lt;50,000/microL; international normalized ratio &gt;1.5). (See
         <a class="medical medical_review" href="/z/d/html/2553.html" rel="external">
          "Gastrointestinal endoscopy in patients with disorders of hemostasis"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H7">
         <span class="h1">
          CELIAC PLEXUS INTERVENTIONS
         </span>
        </p>
        <p class="headingAnchor" id="H1805345269">
         <span class="h2">
          Neurolytic block (celiac plexus neurolysis)
         </span>
        </p>
        <p class="headingAnchor" id="H3374629549">
         <span class="h3">
          Patient selection
         </span>
         <span class="headingEndMark">
          —
         </span>
         Neurolytic block is indicated for relief of abdominal pain in patients with inoperable pancreatic cancer (or a malignancy with pancreatic metastasis) who require opioid analgesics or who do not wish to use opioids [
         <a href="#rid4">
          4
         </a>
         ]. EUS-guided celiac plexus neurolysis produces analgesia by destroying (ie, causing lysis in) afferent neural pathways or sympathetic structures involved in pain transmission. Neural destruction can be achieved by injecting material (typically alcohol plus local anesthetic) that damages the nerve.
        </p>
        <p>
         Early referral for EUS-guided-celiac plexus neurolysis has been associated with better pain control and less opioid consumption compared with waiting until after failure to obtain pain relief with opioids [
         <a href="#rid5">
          5,6
         </a>
         ]. When on-site cytopathology is available and diagnostic for inoperable malignancy, we may perform EUS-guided neurolytic block at the time of the initial endoscopic evaluation. Early pancreatic cancer pain appears to derive mainly from the celiac plexus, while pain during the terminal stages of disease may also involve other visceral and somatic nerves. Thus, EUS-guided neurolysis performed soon after the onset of pain from pancreatic cancer may increase the rate of response. (See
         <a class="medical medical_review" href="/z/d/html/2505.html" rel="external">
          "Supportive care for locally advanced or metastatic exocrine pancreatic cancer", section on 'Pain'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H655421058">
         <span class="h3">
          Patient preparation
         </span>
         <span class="headingEndMark">
          —
         </span>
         The preprocedure preparation for patients is similar to that described for patients undergoing upper gastrointestinal endoscopy (see
         <a class="medical medical_review" href="/z/d/html/13928.html" rel="external">
          "Overview of upper gastrointestinal endoscopy (esophagogastroduodenoscopy)", section on 'Patient preparation'
         </a>
         ):
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Adjusting anticoagulation medications – Most patients do not need to discontinue
         <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">
          aspirin
         </a>
         when undergoing EUS-guided celiac plexus interventions. While holding nonsteroidal anti-inflammatories (NSAIDs) is not required for all patients, NSAID management is typically guided by endoscopist preference.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The procedure-related bleeding risk for patients on anticoagulants and/or nonaspirin antiplatelet agents is high  (
         <a class="graphic graphic_table graphicRef50700" href="/z/d/graphic/50700.html" rel="external">
          table 1
         </a>
         ). The management of antiplatelet and anticoagulant therapy in patients undergoing endoscopy is typically individualized, managed in conjunction with the prescribing specialist, and is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/2632.html" rel="external">
          "Management of antiplatelet agents in patients undergoing endoscopic procedures"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2609.html" rel="external">
          "Management of anticoagulants in patients undergoing endoscopic procedures"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Antibiotic prophylaxis – Antibiotic prophylaxis is not typically given to patients prior to EUS-guided injection of dehydrated alcohol because alcohol is bactericidal [
         <a href="#rid7">
          7
         </a>
         ]. (See
         <a class="local">
          'Procedure'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Intravenous hydration – Before the procedure, patients are hydrated with a crystalloid solution intravenously to minimize the risk of hypotension during or after the procedure. (See
         <a class="local">
          'Intervention-related'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The choice of fluid, volume of fluid, and timing of administration are individualized based on patient comorbidities (eg, congestive heart failure), preprocedure volume status, and anesthetic agent(s). Adverse effects of anesthetic agents (eg,
         <a class="drug drug_general" data-topicid="9826" href="/z/d/drug information/9826.html" rel="external">
          propofol
         </a>
         ) and the approach to procedural fluid management is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/14942.html" rel="external">
          "Intraoperative fluid management"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/105511.html" rel="external">
          "Anesthesia for gastrointestinal endoscopy in adults"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Anesthesia – The procedure is typically performed on an outpatient basis using monitored anesthesia care. Anesthesia for endoscopic procedures is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/105511.html" rel="external">
          "Anesthesia for gastrointestinal endoscopy in adults"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3485715554">
         <span class="h3">
          Procedure
         </span>
        </p>
        <p class="headingAnchor" id="H1312209621">
         <span class="h4">
          Equipment
         </span>
         <span class="headingEndMark">
          —
         </span>
         EUS is performed with an echoendoscope (an endoscope with an ultrasound transducer engineered into its tip). The curvilinear array echoendoscope provides a 180-degree view that is in the same plane as the shaft of the echoendoscope, thereby permitting real-time visualization of the needle as it is advanced into the periluminal space.
        </p>
        <p>
         Choice of needle is based on endoscopist preference and needle availability, and no specific needle type or size has been proven superior. Needle options include (see
         <a class="medical medical_review" href="/z/d/html/2656.html" rel="external">
          "Endoscopic ultrasound-guided fine needle aspiration in the gastrointestinal tract", section on 'Equipment'
         </a>
         ):
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A fine needle aspiration (FNA) needle, ranging in size from 19- to 22-gauge. The 22-gauge FNA needle has been commonly used for celiac plexus interventions.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A dedicated, 20-gauge celiac plexus needle with multiple side holes that facilitate spreading of the injected material.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H8">
         <span class="h4">
          Technique
         </span>
         <span class="headingEndMark">
          —
         </span>
         Technique for celiac plexus intervention using EUS guidance is summarized as follows [
         <a href="#rid8">
          8
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Position the patient in the left lateral decubitus position.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Advance the curvilinear array echoendoscope through the mouth to the posterior lesser curve of the fundus of the stomach to identify the aorta, which appears in a longitudinal plane  (
         <a class="graphic graphic_diagnosticimage graphicRef77966" href="/z/d/graphic/77966.html" rel="external">
          image 1
         </a>
         ).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Trace the path of the aorta distally to the celiac trunk, which is the first major vessel branch below the diaphragm. Identify the celiac plexus, which is located anterior and lateral to the celiac trunk. With doppler imaging, confirm the vascular nature of the adjacent structures.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Flush the needle with normal
         <a class="drug drug_general" data-topicid="9929" href="/z/d/drug information/9929.html" rel="external">
          saline
         </a>
         to remove air and then place it through the biopsy channel of the echoendoscope and into the stomach. Secure the needle to the hub of the channel.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Using EUS guidance, direct the needle tip through the gastric wall and into the celiac region (5 to 10 mm along the lateral aspect of the aorta at the level of the celiac trunk origin)  (
         <a class="graphic graphic_figure graphicRef81618" href="/z/d/graphic/81618.html" rel="external">
          figure 1
         </a>
         and
         <a class="graphic graphic_diagnosticimage graphicRef79530" href="/z/d/graphic/79530.html" rel="external">
          image 2
         </a>
         ). For bilateral injection, begin by targeting the region to the right side of the celiac artery. We typically target the right side first because it is farther from the ultrasound transducer and more difficult to visualize than the left side.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Flush the needle with 3 mL of normal
         <a class="drug drug_general" data-topicid="9929" href="/z/d/drug information/9929.html" rel="external">
          saline
         </a>
         to remove any tissue that was acquired during needle insertion. Arterial extension tubing attached to the needle can be used to facilitate flushing the needle with saline and the subsequent aspiration test.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Prior to each drug injection, perform an aspiration test by applying suction to a 10 mL syringe for 15 seconds to confirm the absence of blood return.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Inject a mixture of dehydrated alcohol USP (anhydrous
         <a class="drug drug_general" data-topicid="9342" href="/z/d/drug information/9342.html" rel="external">
          ethanol for medical use
         </a>
         , also known as absolute alcohol), 20 mL, and
         <a class="drug drug_general" data-topicid="9169" href="/z/d/drug information/9169.html" rel="external">
          bupivacaine
         </a>
         0.25%, 4 mL, (ie, 5:1 ratio). This mixture can be placed in two 12 mL syringes (ie, one syringe for injecting each side of the celiac trunk). The alcohol produces an echogenic cloud and may lead to patient discomfort immediately following injection and resulting in patient movement, despite sedation/anesthesia  (
         <a class="graphic graphic_diagnosticimage graphicRef57496" href="/z/d/graphic/57496.html" rel="external">
          image 3
         </a>
         ).
        </p>
        <p>
        </p>
        <p>
         The volume of alcohol in the injectate mixture varies among clinicians but typically ranges from 10 to 30 mL. Studies have not demonstrated a significant difference in symptom improvement with different volumes of injectate [
         <a href="#rid9">
          9
         </a>
         ].
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         After each drug injection, flush the needle with 3 mL of normal
         <a class="drug drug_general" data-topicid="9929" href="/z/d/drug information/9929.html" rel="external">
          saline
         </a>
         to ensure that the needle lumen is cleared of the drug(s). Seeding of the needle track with alcohol may produce transient but severe post-injection pain.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Repeat the entire process on the opposite side of the celiac trunk.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Before withdrawing the needle from the echoendoscope, flush it with normal
         <a class="drug drug_general" data-topicid="9929" href="/z/d/drug information/9929.html" rel="external">
          saline
         </a>
         3 mL.
        </p>
        <p>
        </p>
        <p>
         Options for technique modification include:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Unilateral injection – For patients with bulky lymphadenopathy, a large pancreatic mass, and/or advanced cancer that results in altered anatomy, the procedure may be technically limited. For such patients, one injection may be performed on either the right or left side of the region surrounding the celiac artery.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3002450892">
         <span class="h3">
          Postprocedure care
         </span>
         <span class="headingEndMark">
          —
         </span>
         After the procedure, patients are recovered from sedation or anesthesia and are monitored prior to discharge. (See
         <a class="medical medical_review" href="/z/d/html/105511.html" rel="external">
          "Anesthesia for gastrointestinal endoscopy in adults", section on 'Post-anesthesia care'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H9">
         <span class="h3">
          Efficacy
         </span>
         <span class="headingEndMark">
          —
         </span>
         Data from several trials and meta-analyses have reported that EUS-guided celiac plexus neurolysis was effective for alleviating pancreatic cancer pain in 50 to 80 percent of patients for approximately two to three months [
         <a href="#rid6">
          6,10-13
         </a>
         ]. EUS-guided neurolysis is one method for managing pain from pancreatic cancer, while most patients require pharmacologic therapy (eg, opioids, nonsteroidal anti-inflammatory medications). The approach to pain management for patients with pancreatic cancer is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/2505.html" rel="external">
          "Supportive care for locally advanced or metastatic exocrine pancreatic cancer", section on 'Pain'
         </a>
         .)
        </p>
        <p>
         The neurolytic agent used during EUS-guided neurolysis induces a local inflammatory reaction, followed by fibrosis during the healing process [
         <a href="#rid14">
          14
         </a>
         ].
        </p>
        <p>
         For EUS-guided celiac plexus interventions, we typically use bilateral injection (ie, drug injection on both sides of the celiac artery) when technically feasible to optimize distribution of the injectate over the celiac plexus. However, data on drug injection placement have been mixed. In two meta-analyses, short-term pain relief was not significantly different for EUS-guided celiac plexus neurolysis with bilateral injection (ie, administering the injectate in two divided doses on each side of the root of the celiac artery) compared with unilateral injection (ie, injecting of the total volume immediately anteriorly to the root of the celiac artery) [
         <a href="#rid11">
          11,15,16
         </a>
         ]. In a study including 160 patients, EUS-guided celiac plexus neurolytic or nonneurolytic block with bilateral injection was associated with greater reduction in pain compared with central injection (mean percent pain reduction: 70 versus 46 percent) [
         <a href="#rid17">
          17
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H3338100829">
         <span class="h2">
          Nonneurolytic block (celiac plexus block)
         </span>
        </p>
        <p class="headingAnchor" id="H3341795857">
         <span class="h3">
          Patient selection
         </span>
         <span class="headingEndMark">
          —
         </span>
         EUS-guided celiac plexus nonneurolytic block is typically used for short-term relief of abdominal pain in patients with chronic pancreatitis who require opioid analgesics or do not wish to use opioids. The nonneurolytic block typically involves injecting local anesthetic combined with a glucocorticoid into or around the celiac plexus. The management of chronic pancreatitis is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/5647.html" rel="external">
          "Chronic pancreatitis: Management"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3738880721">
         <span class="h3">
          Procedure
         </span>
         <span class="headingEndMark">
          —
         </span>
         The procedure for EUS-guided celiac plexus block, including patient preparation, equipment, technique, and postprocedure care, is similar to the procedure for EUS-guided neurolysis in addition to the following [
         <a href="#rid18">
          18
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Patient preparation
         </strong>
         – Antibiotic prophylaxis is given to patients receiving injection of a local anesthetic, with or without a glucocorticoid. The antibiotic regimen typically consists of a fluoroquinolone, similar to other interventional EUS procedures and as presented in the table  (
         <a class="graphic graphic_table graphicRef54121" href="/z/d/graphic/54121.html" rel="external">
          table 2
         </a>
         ). (See
         <a class="medical medical_review" href="/z/d/html/2545.html" rel="external">
          "Antibiotic prophylaxis for gastrointestinal endoscopic procedures", section on 'Endoscopic ultrasound'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Technique
         </strong>
         – For celiac plexus nonneurolytic block, agents for injection typically are a local anesthetic (
         <a class="drug drug_general" data-topicid="9169" href="/z/d/drug information/9169.html" rel="external">
          bupivacaine
         </a>
         0.25%), often combined with a glucocorticoid (
         <a class="drug drug_general" data-topicid="10015" href="/z/d/drug information/10015.html" rel="external">
          triamcinolone
         </a>
         suspension 40 mg/mL):
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         For bilateral injection, inject
         <a class="drug drug_general" data-topicid="9169" href="/z/d/drug information/9169.html" rel="external">
          bupivacaine
         </a>
         0.25% (4 mL each side), followed by
         <a class="drug drug_general" data-topicid="10015" href="/z/d/drug information/10015.html" rel="external">
          triamcinolone
         </a>
         80 mg (40 mg/mL) (ie, 40 mg each side).
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         For central or unilateral injection, inject
         <a class="drug drug_general" data-topicid="9169" href="/z/d/drug information/9169.html" rel="external">
          bupivacaine
         </a>
         0.25% (8 mL), followed by
         <a class="drug drug_general" data-topicid="10015" href="/z/d/drug information/10015.html" rel="external">
          triamcinolone
         </a>
         80 mg (40 mg/mL)
        </p>
        <p>
        </p>
        <p>
         We use bilateral injection when technically possible to optimize distribution of the injectate over the plexus, although supporting data are lacking.
        </p>
        <p class="headingAnchor" id="H10">
         <span class="h3">
          Efficacy
         </span>
         <span class="headingEndMark">
          —
         </span>
         Celiac plexus nonneurolytic block is an option for treating intractable pain related to chronic pancreatitis. The injection of a local anesthetic often combined with a glucocorticoid into the celiac plexus interferes with the perception of pain by disrupting nerve transmission [
         <a href="#rid18">
          18,19
         </a>
         ]. In a meta-analysis of six studies including 221 patients with chronic pancreatitis, EUS-guided celiac plexus block (local anesthetic plus glucocorticoid) was associated with alleviation of abdominal pain in 52 percent of patients [
         <a href="#rid12">
          12
         </a>
         ]. In a subsequent cohort study including 248 patients with chronic pancreatitis, EUS-guided celiac plexus block was associated with pain relief in 177 patients (76 percent) and the median duration of effect was 10 weeks [
         <a href="#rid18">
          18
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/5647.html" rel="external">
          "Chronic pancreatitis: Management", section on 'Celiac plexus block'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H4293992479">
         <span class="h1">
          ADVERSE EVENTS
         </span>
         <span class="headingEndMark">
          —
         </span>
         EUS-guided neurolytic and nonneurolytic blocks are relatively safe procedures, but minor and major adverse events can occur. Some adverse events are due to the endoscopy itself, the procedural sedation, or the interventional procedure. In a systematic review of 20 studies including 661 patients who had EUS-guided neurolysis and 481 patients who had EUS-guided nonneurolytic block, the overall complication rate for neurolysis was 21 percent and for nonneurolytic block was 7 percent [
         <a href="#rid20">
          20
         </a>
         ]. Most adverse events were minor and self-limited (usually lasting &lt;48 hours). For patients with celiac plexus neurolysis, the most common adverse events were related to sympathetic blockage (self-limited diarrhea in 7 percent of patients and transient hypotension in 4 percent of patients) [
         <a href="#rid21">
          21
         </a>
         ]. Major adverse events were rare and were reported in less than one percent of patients undergoing EUS-guided neurolysis or nonneurolytic block. (See
         <a class="local">
          'Intervention-related'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H1821391584">
         <span class="h2">
          Endoscopy-related
         </span>
         <span class="headingEndMark">
          —
         </span>
         Adverse events associated with EUS may be due to the upper gastrointestinal endoscopy itself (without intervention) and/or the associated sedation and anesthesia. These adverse events are discussed in more detail separately. (See
         <a class="medical medical_review" href="/z/d/html/2599.html" rel="external">
          "Adverse events related to procedural sedation for gastrointestinal endoscopy in adults"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/13928.html" rel="external">
          "Overview of upper gastrointestinal endoscopy (esophagogastroduodenoscopy)", section on 'Complications'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H129530721">
         <span class="h2">
          Intervention-related
         </span>
         <span class="headingEndMark">
          —
         </span>
         Reported adverse events of EUS-guided neurolytic and nonneurolytic blocks have included [
         <a href="#rid20">
          20-22
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Hypotension (usually transient)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Diarrhea (usually self-limited)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Postprocedural pain/exacerbation of existing pain (usually lasting &lt;48 hours) [
         <a href="#rid23">
          23
         </a>
         ]
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Infection (abscess, empyema) (rare) [
         <a href="#rid7">
          7,24,25
         </a>
         ]
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Bleeding (rare) [
         <a href="#rid17">
          17
         </a>
         ]
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Paraplegia (rare) [
         <a href="#rid26">
          26-29
         </a>
         ]
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Diaphragmatic paralysis (rare) [
         <a href="#rid30">
          30
         </a>
         ]
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Ischemia (rare) [
         <a href="#rid31">
          31,32
         </a>
         ]
        </p>
        <p>
        </p>
        <p>
         Hypotension that occurs during the procedure or recovery phase is initially managed with intravenous hydration. Management of hemodynamic issues following anesthesia is discussed in more detail separately. (See
         <a class="medical medical_review" href="/z/d/html/94349.html" rel="external">
          "Cardiovascular problems in the post-anesthesia care unit (PACU)"
         </a>
         .)
        </p>
        <p>
         Transient diarrhea and hypotension are common manifestations of the interruption of the sympathetic supply to the intestines and blood vessels that can occur following EUS-guided neurolytic or nonneurolytic blocks [
         <a href="#rid20">
          20
         </a>
         ]. The celiac plexus is a dense network of abdominal visceral afferent nerve fibers and sympathetic fibers of the splanchnic nerves. Thus, interruption of the plexus not only reduces pain transmission from the abdominal organs (pancreas, liver, stomach, kidney, small bowel, and colon) but can also result in a sympathetic blockade. Clinical manifestations of sympathetic blockade can include diarrhea and hypotension due to relatively unopposed visceral parasympathetic activity.
        </p>
        <p>
         Paralysis and acute spinal cord ischemia have been rarely reported after celiac plexus neurolysis. Case reports suggested various causes of infarction of the L1/L2 vertebrae (eg, embolic occlusion of the lumbar arteries, needle injury, injection of alcohol into the Adamkiewicz artery) [
         <a href="#rid33">
          33
         </a>
         ]. However, very few cases of irreversible paraplegia have been reported [
         <a href="#rid16">
          16
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H11">
         <span class="h1">
          OTHER EUS-GUIDED INTERVENTIONS
         </span>
        </p>
        <p class="headingAnchor" id="H2600752893">
         <span class="h2">
          Celiac ganglia neurolytic block
         </span>
         <span class="headingEndMark">
          —
         </span>
         Several studies have noted that the celiac ganglia can be visualized with EUS guidance in approximately 60 to 90 percent of patients. Thus, neurolytic block (neurolysis) can be performed by directly injecting material (local anesthetic, alcohol) into individual celiac ganglia [
         <a href="#rid8">
          8,34-37
         </a>
         ].
        </p>
        <p>
         After visualizing the celiac artery with EUS, the celiac ganglia typically are seen to the left of the celiac artery, between the aorta and left adrenal gland. The celiac ganglia are predominantly hypoechoic, oval or round structures with irregular margins, and ranging in diameter from 2 to 20 mm and in number from one to five  (
         <a class="graphic graphic_diagnosticimage graphicRef70232" href="/z/d/graphic/70232.html" rel="external">
          image 4
         </a>
         ) [
         <a href="#rid8">
          8,38
         </a>
         ]. The ganglia are hypoechoic in contrast to the surrounding retroperitoneal fat and often display similar echogenicity to that of the left adrenal gland. Central echo-rich strands or foci are present, and hypoechoic thread-like structures can be seen arising from ganglia. These threads connect to the ganglia, or course along the anterior surface of the celiac trunk. Color doppler ultrasonography confirms little or no flow within these structures.
        </p>
        <p class="headingAnchor" id="H13">
         <span class="h3">
          Procedure
         </span>
         <span class="headingEndMark">
          —
         </span>
         All aspects of the procedure including patient preparation, equipment, and postprocedure care are similar to that of celiac plexus neurolysis, except for the following modifications  (
         <a class="graphic graphic_figure graphicRef76500" href="/z/d/graphic/76500.html" rel="external">
          figure 2
         </a>
         ) (see
         <a class="local">
          'Neurolytic block (celiac plexus neurolysis)'
         </a>
         above):
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Advance the needle tip through the gastric wall and to a distance determined by ganglion size within the axis of the needle plane:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         For ganglion size &lt;10 mm in diameter, insert the needle to the center of the ganglion.
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         For ganglion size ≥10 mm in diameter, advance the needle tip to the deepest point within the ganglion.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Inject a mixture of dehydrated alcohol USP (anhydrous
         <a class="drug drug_general" data-topicid="9342" href="/z/d/drug information/9342.html" rel="external">
          ethanol for medical use
         </a>
         , also known as absolute alcohol) and
         <a class="drug drug_general" data-topicid="9169" href="/z/d/drug information/9169.html" rel="external">
          bupivacaine
         </a>
         0.25% (mixed in a 1:1 ratio) as the needle is slowly withdrawn from the ganglion; this results in a hyperechoic appearance. The volume of the drug mixture that is injected into each ganglion depends on ganglion size and typically ranges from 1 to 5 mL per ganglion.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Repeat the injection while targeting all visualized ganglia.
        </p>
        <p>
        </p>
        <p>
         Direct injection commonly results in enlargement of the ganglia  (
         <a class="graphic graphic_diagnosticimage graphicRef58737" href="/z/d/graphic/58737.html" rel="external">
          image 5
         </a>
         ). Intra-ganglia injection is typically accompanied by the immediate onset of pain, which manifests as an abrupt increase in patient movement, attempted verbalization, altered pulse and respiration despite monitored anesthesia care. These manifestations resolve within a few seconds after ganglia injection, and have been associated with improved therapeutic response [
         <a href="#rid35">
          35
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H14">
         <span class="h3">
          Efficacy
         </span>
         <span class="headingEndMark">
          —
         </span>
         Data on efficacy of celiac ganglia neurolysis are mixed. Small studies have suggested that direct injection of the celiac ganglia was associated with reduction in pain for patients with pancreatic cancer [
         <a href="#rid35">
          35,39
         </a>
         ], however, a subsequent trial indicated that celiac ganglia neurolysis resulted in decreased survival without a pain control benefit [
         <a href="#rid40">
          40
         </a>
         ]. In a trial including 110 patients with unresectable pancreatic cancer, there was no significant difference in rates of pain response at 12 weeks or adverse events for celiac ganglia neurolysis compared with celiac plexus neurolysis. However, celiac ganglia neurolysis resulted in shorter survival time (5.6 versus 10.5 months; hazard ratio 1.49, 95% CI 1.02-2.19). However, in an earlier trial including 34 patients with pain related to abdominal cancer, EUS-guided celiac ganglia neurolysis was associated with higher rates of treatment response (74 versus 46 percent) and complete pain relief (50 versus 18 percent) compared with celiac plexus neurolysis [
         <a href="#rid39">
          39
         </a>
         ]. There was no significant difference with regard to duration of pain relief or adverse events.
        </p>
        <p>
         Additional data from randomized controlled trials are needed to assess the outcomes of EUS-guided direct injection of celiac ganglia before it can be used routinely in clinical practice. The use of celiac ganglia neurolysis for pain management should be individualized based on factors such as severity of pain and response to pain medications and other interventions. (See
         <a class="medical medical_review" href="/z/d/html/2505.html" rel="external">
          "Supportive care for locally advanced or metastatic exocrine pancreatic cancer"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H932935060">
         <span class="h2">
          Broad plexus neurolytic block
         </span>
         <span class="headingEndMark">
          —
         </span>
         EUS-guided broad plexus neurolysis involves injecting the neurolytic agent at the level of the superior mesenteric artery (rather than the celiac artery), resulting in a broader distribution of neurolytic block. Broad plexus neurolytic block is typically used for patients without improvement in pain following celiac plexus neurolytic block. Limited data have suggested that broad plexus neurolysis was associated with improvement of cancer-related pain [
         <a href="#rid41">
          41,42
         </a>
         ]. In an observational study including 112 patients with abdominal cancer-related pain, EUS guided broad plexus neurolysis was associated with good pain response (defined as decrease in pain score without additional opioid requirement) in 76 patients (68 percent) at four weeks [
         <a href="#rid42">
          42
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H4152152256">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/112065.html" rel="external">
          "Society guideline links: Chronic pancreatitis and pancreatic exocrine insufficiency"
         </a>
         and
         <a class="medical medical_society_guidelines" href="/z/d/html/119434.html" rel="external">
          "Society guideline links: Cancer pain"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H19">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Anatomy of the celiac plexus
         </strong>
         – The celiac plexus is a dense network of nerves including sympathetic and parasympathetic efferent fibers and visceral sensory afferent fibers that innervate the upper abdominal organs. The celiac plexus mediates the sensation of pain from the pancreas and includes right and left ganglia that lie anterolateral to the aorta at the origin of the celiac trunk (ie, the first large vessel to branch from the aorta below the diaphragm). (See
         <a class="local">
          'Anatomy of the celiac plexus'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Terminology
         </strong>
         –
         <strong>
         </strong>
         Endoscopic ultrasound (EUS)-guided celiac plexus interventions involve drug injections at the level of the celiac artery (see
         <a class="local">
          'Terminology'
         </a>
         above):
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Celiac plexus neurolysis (neurolytic block) – Celiac plexus neurolytic block is an intervention that permanently alters the affected nerve.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Celiac plexus block (nonneurolytic block) – Celiac plexus nonneurolytic block is an intervention that interrupts nerve transmission without permanently injuring the affected nerve.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Additional techniques – Celiac ganglia neurolysis (directly injecting the neurolytic agent at the celiac ganglia via EUS) and broad plexus neurolysis (injecting the neurolytic agent at the level of the superior mesenteric artery)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Contraindications
         </strong>
         – There are few contraindications to EUS-guided celiac plexus interventions including hemodynamic instability, inability to tolerate anesthesia/sedation, and coagulation disorders. (See
         <a class="local">
          'Contraindications'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Patient selection
         </strong>
         – Patients with inoperable cancer and abdominal pain requiring opioid analgesics (or patients with pain who do not wish to use opioids) are candidates for celiac plexus neurolysis (neurolysis). EUS-guided celiac plexus neurolysis produces analgesia by destroying afferent neural pathways or sympathetic structures involved in pain transmission.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Celiac plexus nonneurolytic block is an option for treating intractable pain related to chronic pancreatitis. The injection temporarily interferes with the perception of pain by disrupting nerve transmission. (See
         <a class="local">
          'Patient selection'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Technique
         </strong>
         – The technical procedure of EUS-guided celiac plexus neurolysis includes identifying the celiac plexus, advancing the needle through the gastric wall and into the celiac region, flushing the needle with
         <a class="drug drug_general" data-topicid="9929" href="/z/d/drug information/9929.html" rel="external">
          saline
         </a>
         , applying suction to confirm absence of blood return, and injecting the drug, typically with a bilateral approach. For some patients with bulky lymphadenopathy or large pancreatic tumors, a unilateral approach for injection is an alternative. (See
         <a class="local">
          'Technique'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Adverse events
         </strong>
         – EUS-guided celiac plexus interventions are generally safe procedures, and serious adverse events are infrequently reported. Transient diarrhea and hypotension are common manifestations of the sympathetic blockade that can occur following EUS-guided neurolytic or nonneurolytic blocks. Hypotension is managed with intravenous hydration before, during, and after the procedure. (See
         <a class="local">
          'Adverse Events'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1560049181">
         <span class="h1">
          ACKNOWLEDGMENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         The UpToDate editorial staff acknowledges Michael Levy, MD (deceased), who contributed to earlier versions of this topic review.
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Sachdev AH, Gress FG. Celiac Plexus Block and Neurolysis: A Review. Gastrointest Endosc Clin N Am 2018; 28:579.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ward EM, Rorie DK, Nauss LA, Bahn RC. The celiac ganglia in man: normal anatomic variations. Anesth Analg 1979; 58:461.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schmulewitz N, Hawes R. EUS-guided celiac plexus neurolysis--technique and indication. Endoscopy 2003; 35:S49.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hickman K, Godfrey E, Ajithkumar T. Endoscopic ultrasound-guided neurolysis in advanced pancreatic cancer: current status. BMJ Support Palliat Care 2022; 12:22.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ischia S, Ischia A, Polati E, Finco G. Three posterior percutaneous celiac plexus block techniques. A prospective, randomized study in 61 patients with pancreatic cancer pain. Anesthesiology 1992; 76:534.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wyse JM, Carone M, Paquin SC, et al. Randomized, double-blind, controlled trial of early endoscopic ultrasound-guided celiac plexus neurolysis to prevent pain progression in patients with newly diagnosed, painful, inoperable pancreatic cancer. J Clin Oncol 2011; 29:3541.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gress F, Schmitt C, Sherman S, et al. Endoscopic ultrasound-guided celiac plexus block for managing abdominal pain associated with chronic pancreatitis: a prospective single center experience. Am J Gastroenterol 2001; 96:409.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Levy M, Rajan E, Keeney G, et al. Neural ganglia visualized by endoscopic ultrasound. Am J Gastroenterol 2006; 101:1787.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Abdel-Ghaffar ME, Ismail SA, Ismail RA, et al. Comparison Between Two Volumes of 70% Alcohol in Single Injection Ultrasound-Guided Celiac Plexus Neurolysis: A Randomized Controlled Trial. Pain Physician 2022; 25:293.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lou S. Endoscopic Ultrasound-guided Celiac Plexus Neurolysis to Alleviate Intractable Pain Caused by Advanced Pancreatic Cancer. Surg Laparosc Endosc Percutan Tech 2019; 29:472.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Puli SR, Reddy JB, Bechtold ML, et al. EUS-guided celiac plexus neurolysis for pain due to chronic pancreatitis or pancreatic cancer pain: a meta-analysis and systematic review. Dig Dis Sci 2009; 54:2330.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kaufman M, Singh G, Das S, et al. Efficacy of endoscopic ultrasound-guided celiac plexus block and celiac plexus neurolysis for managing abdominal pain associated with chronic pancreatitis and pancreatic cancer. J Clin Gastroenterol 2010; 44:127.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           McGreevy K, Hurley RW, Erdek MA, et al. The effectiveness of repeat celiac plexus neurolysis for pancreatic cancer: a pilot study. Pain Pract 2013; 13:89.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wyse JM, Battat R, Sun S, et al. Practice guidelines for endoscopic ultrasound-guided celiac plexus neurolysis. Endosc Ultrasound 2017; 6:369.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lu F, Dong J, Tang Y, et al. Bilateral vs. unilateral endoscopic ultrasound-guided celiac plexus neurolysis for abdominal pain management in patients with pancreatic malignancy: a systematic review and meta-analysis. Support Care Cancer 2018; 26:353.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Koulouris AI, Alexandre L, Hart AR, Clark A. Endoscopic ultrasound-guided celiac plexus neurolysis (EUS-CPN) technique and analgesic efficacy in patients with pancreatic cancer: A systematic review and meta-analysis. Pancreatology 2021; 21:434.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sahai AV, Lemelin V, Lam E, Paquin SC. Central vs. bilateral endoscopic ultrasound-guided celiac plexus block or neurolysis: a comparative study of short-term effectiveness. Am J Gastroenterol 2009; 104:326.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sey MS, Schmaltz L, Al-Haddad MA, et al. Effectiveness and safety of serial endoscopic ultrasound-guided celiac plexus block for chronic pancreatitis. Endosc Int Open 2015; 3:E56.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fusaroli P, Caletti G. Is there a role for celiac plexus block for chronic pancreatitis? Endosc Int Open 2015; 3:E60.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Alvarez-Sánchez MV, Jenssen C, Faiss S, Napoléon B. Interventional endoscopic ultrasonography: an overview of safety and complications. Surg Endosc 2014; 28:712.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nagels W, Pease N, Bekkering G, et al. Celiac plexus neurolysis for abdominal cancer pain: a systematic review. Pain Med 2013; 14:1140.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           O'Toole TM, Schmulewitz N. Complication rates of EUS-guided celiac plexus blockade and neurolysis: results of a large case series. Endoscopy 2009; 41:593.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gunaratnam NT, Sarma AV, Norton ID, Wiersema MJ. A prospective study of EUS-guided celiac plexus neurolysis for pancreatic cancer pain. Gastrointest Endosc 2001; 54:316.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Muscatiello N, Panella C, Pietrini L, et al. Complication of endoscopic ultrasound-guided celiac plexus neurolysis. Endoscopy 2006; 38:858.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lalueza A, López-Medrano F, del Palacio A, et al. Cladosporium macrocarpum brain abscess after endoscopic ultrasound-guided celiac plexus block. Endoscopy 2011; 43 Suppl 2 UCTN:E9.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mittal MK, Rabinstein AA, Wijdicks EF. Pearls &amp; oy-sters: Acute spinal cord infarction following endoscopic ultrasound-guided celiac plexus neurolysis. Neurology 2012; 78:e57.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fujii L, Clain JE, Morris JM, Levy MJ. Anterior spinal cord infarction with permanent paralysis following endoscopic ultrasound celiac plexus neurolysis. Endoscopy 2012; 44 Suppl 2 UCTN:E265.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Minaga K, Kitano M, Imai H, et al. Acute spinal cord infarction after EUS-guided celiac plexus neurolysis. Gastrointest Endosc 2016; 83:1039.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Köker IH, Aralaşmak A, Ünver N, et al. Spinal cord ischemia after endoscopic ultrasound guided celiac plexus neurolysis: case report and review of the literature. Scand J Gastroenterol 2017; 52:1158.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mulhall AM, Rashkin MC, Pina EM. Bilateral Diaphragmatic Paralysis: A Rare Complication Related to Endoscopic Ultrasound-Guided Celiac Plexus Neurolysis. Ann Am Thorac Soc 2016; 13:1660.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Loeve US, Mortensen MB. Lethal necrosis and perforation of the stomach and the aorta after multiple EUS-guided celiac plexus neurolysis procedures in a patient with chronic pancreatitis. Gastrointest Endosc 2013; 77:151.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jang HY, Cha SW, Lee BH, et al. Hepatic and splenic infarction and bowel ischemia following endoscopic ultrasound-guided celiac plexus neurolysis. Clin Endosc 2013; 46:306.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wyse JM, Sahai AV. EUS-guided celiac plexus neurolysis for pancreas cancer - Finally established or still under review? Best Pract Res Clin Gastroenterol 2022; 60-61:101809.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gleeson FC, Levy MJ, Papachristou GI, et al. Frequency of visualization of presumed celiac ganglia by endoscopic ultrasound. Endoscopy 2007; 39:620.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Levy MJ, Topazian MD, Wiersema MJ, et al. Initial evaluation of the efficacy and safety of endoscopic ultrasound-guided direct Ganglia neurolysis and block. Am J Gastroenterol 2008; 103:98.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ha TI, Kim GH, Kang DH, et al. Detection of celiac ganglia with radial scanning endoscopic ultrasonography. Korean J Intern Med 2008; 23:5.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kappelle WFW, Bleys RLAW, van Wijck AJM, et al. EUS-guided celiac ganglia neurolysis: a clinical and human cadaver study (with video). Gastrointest Endosc 2017; 86:655.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Minaga K, Takenaka M, Kamata K, et al. Alleviating Pancreatic Cancer-Associated Pain Using Endoscopic Ultrasound-Guided Neurolysis. Cancers (Basel) 2018; 10.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Doi S, Yasuda I, Kawakami H, et al. Endoscopic ultrasound-guided celiac ganglia neurolysis vs. celiac plexus neurolysis: a randomized multicenter trial. Endoscopy 2013; 45:362.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Levy MJ, Gleeson FC, Topazian MD, et al. Combined Celiac Ganglia and Plexus Neurolysis Shortens Survival, Without Benefit, vs Plexus Neurolysis Alone. Clin Gastroenterol Hepatol 2019; 17:728.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sakamoto H, Kitano M, Kamata K, et al. EUS-guided broad plexus neurolysis over the superior mesenteric artery using a 25-gauge needle. Am J Gastroenterol 2010; 105:2599.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Minaga K, Kitano M, Sakamoto H, et al. Predictors of pain response in patients undergoing endoscopic ultrasound-guided neurolysis for abdominal pain caused by pancreatic cancer. Therap Adv Gastroenterol 2016; 9:483.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 5659 Version 32.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30241645" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Celiac Plexus Block and Neurolysis: A Review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/574729" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : The celiac ganglia in man: normal anatomic variations.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12929055" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : EUS-guided celiac plexus neurolysis--technique and indication.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34635545" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Endoscopic ultrasound-guided neurolysis in advanced pancreatic cancer: current status.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1550278" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Three posterior percutaneous celiac plexus block techniques. A prospective, randomized study in 61 patients with pancreatic cancer pain.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21844506" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Randomized, double-blind, controlled trial of early endoscopic ultrasound-guided celiac plexus neurolysis to prevent pain progression in patients with newly diagnosed, painful, inoperable pancreatic cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11232683" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Endoscopic ultrasound-guided celiac plexus block for managing abdominal pain associated with chronic pancreatitis: a prospective single center experience.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16780554" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Neural ganglia visualized by endoscopic ultrasound.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35652769" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Comparison Between Two Volumes of 70% Alcohol in Single Injection Ultrasound-Guided Celiac Plexus Neurolysis: A Randomized Controlled Trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31107855" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Endoscopic Ultrasound-guided Celiac Plexus Neurolysis to Alleviate Intractable Pain Caused by Advanced Pancreatic Cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19137428" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : EUS-guided celiac plexus neurolysis for pain due to chronic pancreatitis or pancreatic cancer pain: a meta-analysis and systematic review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19826273" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Efficacy of endoscopic ultrasound-guided celiac plexus block and celiac plexus neurolysis for managing abdominal pain associated with chronic pancreatitis and pancreatic cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22568823" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : The effectiveness of repeat celiac plexus neurolysis for pancreatic cancer: a pilot study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29251270" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Practice guidelines for endoscopic ultrasound-guided celiac plexus neurolysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28956176" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Bilateral vs. unilateral endoscopic ultrasound-guided celiac plexus neurolysis for abdominal pain management in patients with pancreatic malignancy: a systematic review and meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33461931" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Endoscopic ultrasound-guided celiac plexus neurolysis (EUS-CPN) technique and analgesic efficacy in patients with pancreatic cancer: A systematic review and meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19174816" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Central vs. bilateral endoscopic ultrasound-guided celiac plexus block or neurolysis: a comparative study of short-term effectiveness.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26134773" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Effectiveness and safety of serial endoscopic ultrasound-guided celiac plexus block for chronic pancreatitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26134774" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Is there a role for celiac plexus block for chronic pancreatitis?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24196551" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Interventional endoscopic ultrasonography: an overview of safety and complications.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23802777" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Celiac plexus neurolysis for abdominal cancer pain: a systematic review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19588286" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Complication rates of EUS-guided celiac plexus blockade and neurolysis: results of a large case series.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11522971" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : A prospective study of EUS-guided celiac plexus neurolysis for pancreatic cancer pain.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17001583" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Complication of endoscopic ultrasound-guided celiac plexus neurolysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21271535" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Cladosporium macrocarpum brain abscess after endoscopic ultrasound-guided celiac plexus block.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22371417" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Pearls&amp;oy-sters: Acute spinal cord infarction following endoscopic ultrasound-guided celiac plexus neurolysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22814912" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Anterior spinal cord infarction with permanent paralysis following endoscopic ultrasound celiac plexus neurolysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26551729" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Acute spinal cord infarction after EUS-guided celiac plexus neurolysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28625083" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Spinal cord ischemia after endoscopic ultrasound guided celiac plexus neurolysis: case report and review of the literature.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27627480" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Bilateral Diaphragmatic Paralysis: A Rare Complication Related to Endoscopic Ultrasound-Guided Celiac Plexus Neurolysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22624792" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Lethal necrosis and perforation of the stomach and the aorta after multiple EUS-guided celiac plexus neurolysis procedures in a patient with chronic pancreatitis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23767046" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Hepatic and splenic infarction and bowel ischemia following endoscopic ultrasound-guided celiac plexus neurolysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36577532" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : EUS-guided celiac plexus neurolysis for pancreas cancer - Finally established or still under review?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17549662" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Frequency of visualization of presumed celiac ganglia by endoscopic ultrasound.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17970834" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Initial evaluation of the efficacy and safety of endoscopic ultrasound-guided direct Ganglia neurolysis and block.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18363273" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Detection of celiac ganglia with radial scanning endoscopic ultrasonography.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28188723" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : EUS-guided celiac ganglia neurolysis: a clinical and human cadaver study (with video).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29462851" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Alleviating Pancreatic Cancer-Associated Pain Using Endoscopic Ultrasound-Guided Neurolysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23616126" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Endoscopic ultrasound-guided celiac ganglia neurolysis vs. celiac plexus neurolysis: a randomized multicenter trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30217513" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Combined Celiac Ganglia and Plexus Neurolysis Shortens Survival, Without Benefit, vs Plexus Neurolysis Alone.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20823834" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : EUS-guided broad plexus neurolysis over the superior mesenteric artery using a 25-gauge needle.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27366217" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Predictors of pain response in patients undergoing endoscopic ultrasound-guided neurolysis for abdominal pain caused by pancreatic cancer.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
